Participate in a Study

Current Studies

Cardiac Trials

Study – EX4758

• eGFR ≥15 and < 60 mL/min/1.73 m2
• Serum hs-CRP ≥2 mg/L at screening
• Evidence of ASCVD by one or more of the following within the last 5 years from screening:
  • Coronary heart disease defined as at least one of the following:
  • Cerebrovascular disease defined as at least one of the following:
  • Symptomatic peripheral artery disease (PAD) defined as at least one of the following:

Type 2 Diabetes Trials:

Study - NN4352

• Male or female, age ≥18 years at the time of signing informed consent.
• Diagnosed with type 2 diabetes mellitus ≥ 10 years prior to the day of screening.
• HbA1c of 7.0-10.0% (53-86 mmol/mol) (both inclusive).

Study - NN4593

• Male or female and age above or equal to 18 years at the time of signing informed consent.
• Diagnosed with type 2 diabetes mellitus ≥ 180 days before screening.
• HbA1c of 7.0-10.0% (53.0-85.8 mmol/mol) (both inclusive) as assessed by central laboratory on the day of screening.
• Treated with once daily or twice-daily basal insulin (neutral protamine hagedorn insulin, insulin
• Body mass index (BMI) ≤ 40.0 kg/m2.

Type 1 or 2 Diabetes Trials:

Study – CIP331

• Individual is 2-80 years of age at time of consent
• A clinical diagnosis of type 1 or type 2 diabetes as determined by investigator for:
  • at least the last 6 months for subjects 2-6 years of age
  • at least the last 12 months for subjects 7-80 years of age
• Subject is on multiple daily injection therapy
• Subject is currently using or is willing to use the Guardian Connect system during the study
• Subject agrees to comply with the study protocol requirements

Study – CIP322

• Individual is 2-75 years of age at time of enrollment.
• Subject has a clinical diagnosis of type 1 or type 2 diabetes for a minimum of 6 months duration as determined via medical record/ source documentation by an individual qualified to make a medical diagnosis.
• Subject is using insulin to treat their diabetes.
• Subject agrees to comply with the study protocol requirements.
• Subject is willing to perform SMBG approximately every 15 minutes /20 minutes during FST.
• If subject is participating in YSI FST, subject has adequate venous access as assessed by investigator or appropriate staff.

Study – NN4635

• Male or female, age above or equal to 18 years at the time of signing informed consent
• Diagnosed with type 2 diabetes mellitus ≥ 180 days prior to the day of screening
• HbA1c of 8.0-10.5%
• BMI ≥ 25 kg/m2
• Stable daily dose(s) for 90 days prior to the day of screening of any of the following treatment regimens:
  • No more than 3 of the following oral anti-diabetic drugs and at least 1 marked with a *:
    • * Metformin
    • * Sulfonylureas
    • * SGLT2 inhibitors
    • *DPP-4 inhibitors